Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JD002 (Beijing Jingda Biotechnology)
- Development stage
- Phase 1
- Lead developer
- Beijing Jingda Biotechnology
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
JD002 is a Chimeric Antigen Receptor Natural Killer (CAR-NK) cell therapy under development by Beijing Jingda Biotechnology Co., Ltd. This innovative cell therapy is designed to harness the inherent cytotoxic capabilities of natural killer cells, enhanced by a chimeric antigen receptor, to specifically target and eliminate cancer cells. It is being investigated for its therapeutic potential in various neoplasms and respiratory diseases, with a primary focus on Non-Small Cell Lung Cancer.
Beyond the preview
Go deeper on JD002 (Beijing Jingda Biotechnology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JD002 (Beijing Jingda Biotechnology).